The Paris System for reporting urinary cytology

• Verfasst von: Nikas, Ilias P. [VerfasserIn]
• Verfasst von: Seide, Svenja [VerfasserIn]
• Verfasst von: Proctor, Tanja [VerfasserIn]
• Verfasst von: Kleinaki, Zoi [VerfasserIn]
• Verfasst von: Kleinaki, Maria [VerfasserIn]
• Verfasst von: Reynolds, Jordan P. [VerfasserIn]
• Titel: The Paris System for reporting urinary cytology
• Titelzusatz: a meta-analysis
• Verf.angabe: Ilias P. Nikas, Svenja Seide, Tanja Proctor, Zoi Kleinaki, Maria Kleinaki and Jordan P. Reynolds
• E-Jahr: 2022
• Jahr: 27 January 2022
• Umfang: 15 S.
• Fussnoten: Gesehen am 12.05.2022 ; This article belongs to the special issue "Precision medicine in urologic oncology: diagnosis, treatment and prognosis"
• Titel Quelle: Enthalten in: Journal of Personalized Medicine
• Ort Quelle: Basel : MDPI, 2011
• Jahr Quelle: 2022
• Band/Heft Quelle: 12(2022), 2, special issue, Artikel-ID 170, Seite 1-15
• ISSN Quelle: 2075-4426
• DOI: doi:10.3390/jpm12020170
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: bladder cancer
• Sach-SW: cytopathology
• Sach-SW: diagnostic accuracy
• Sach-SW: pathology
• Sach-SW: risk of high-grade malignancy (ROHM)
• Sach-SW: sensitivity and specificity
• Sach-SW: tumor
• Sach-SW: urine
• Sach-SW: urothelial carcinoma
• Sach-SW: urothelial neoplasia
• K10plus-PPN: 1801693277

Abstract

The Paris System (TPS) for Reporting Urinary Cytology is a standardized, evidence-based reporting system, comprising seven diagnostic categories: nondiagnostic, negative for high-grade urothelial carcinoma (NHGUC), atypical urothelial cells (AUC), suspicious for high-grade urothelial carcinoma (SHGUC), HGUC, low-grade urothelial neoplasm (LGUN), and other malignancies. This study aimed to calculate the pooled risk of high-grade malignancy (ROHM) of each category and demonstrate the diagnostic accuracy of urine cytology reported with TPS. Four databases (PubMed, Embase, Scopus, Web of Science) were searched. Specific inclusion and exclusion criteria were applied, while data were extracted and analyzed both qualitatively and quantitatively. The pooled ROHM was 17.70% for the nondiagnostic category (95% CI, 0.0650; 0.3997), 13.04% for the NHGUC (95% CI, 0.0932; 0.1796), 38.65% for the AUC (95% CI, 0.3042; 0.4759), 12.45% for the LGUN (95% CI, 0.0431; 0.3101), 76.89 for the SHGUC (95% CI, 0.7063; 0.8216), and 91.79% for the HGUC and other malignancies (95% CI, 0.8722; 0.9482). A summary ROC curve was created and the Area Under the Curve (AUC) was 0.849, while the pooled sensitivity was 0.669 (95% CI, 0.589; 0.741) and false-positive rate was 0.101 (95% CI, 0.063; 0.158). In addition, the pooled DOR of the included studies was 21.258 (95% CI, 14.336; 31.522). TPS assigns each sample into a diagnostic category linked with a specific ROHM, guiding clinical management.